Isotis orthobiologics
IsoTis OrthoBiologics Appoints Gene B. Reu as Vice President of Operations
LAUSANNE, Switzerland, IRVINE, California, August 24 /PRNewswire/ --
IsoTis S.A. (SWX/Euronext: ISON; TSX: ISO), the orthobiologics company, today announced it
has appointed Gene B. Reu as Vice President of Operations.
Pieter Wolters, President and CEO of IsoTis OrthoBiologics said: "We are very pleased
to welcome Gene B. Reu as our new Vice President of Operations. Gene brings more than 20
years of medical device experience to his new position. He has extensive experience in
operations, medical device manufacturing, enterprise resource planning, research and
development and quality affairs. We believe that he is ideally qualified to contribute to
our growth and future development, and to replace Bill Franklin, who, several months ago,
indicated his wish to pursue opportunities outside the company."
Gene B. Reu joins IsoTis from Arthrocare, Inc., where he served as Vice President
& General Manager of Coblation Technologies since 2004. From 2002 to 2004, Mr. Reu
served as VP of Operations at Opus Medical, Inc., which was acquired by Arthrocare, Inc.
in 2004. From 1998 to 2002, Mr. Reu served as VP of R&D and Operations at Cryogen,
Inc. Prior to 1998, Mr. Reu held a number of senior development and quality assurance
positions in the industry, including at Ethicon, Inc. and Baxter Edwards. Mr. Reu holds
B.S. and M.S. degrees in mechanical engineering from the University of Minnesota.
IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary
natural and synthetic bone graft substitutes on the market and others in development, an
established North American independent distribution network, and an expanding
international presence. The company's main commercial operations are based in Irvine, CA,
and its international sales headquarters are based in Lausanne, Switzerland.